| pubmed-article:9255268 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9255268 | lifeskim:mentions | umls-concept:C1257890 | lld:lifeskim |
| pubmed-article:9255268 | lifeskim:mentions | umls-concept:C0006826 | lld:lifeskim |
| pubmed-article:9255268 | lifeskim:mentions | umls-concept:C0092801 | lld:lifeskim |
| pubmed-article:9255268 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:9255268 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:9255268 | lifeskim:mentions | umls-concept:C1518071 | lld:lifeskim |
| pubmed-article:9255268 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:9255268 | pubmed:dateCreated | 1997-8-29 | lld:pubmed |
| pubmed-article:9255268 | pubmed:abstractText | Cladribine (2-chlorodeoxyadenosine;) is a purine analogue with clinical activity against hairy cell leukemia, chronic lymphocytic leukemia and indolent lymphoma. To clarify the toxicity profiles of cladribine, we conducted a phase I and pharmacological study of cladribine with a schedule of seven-day continuous intravenous infusion every 28 days up to a maximum of three cycles. We enrolled 10 previously-treated patients with various lymphoid malignancies. No dose-limiting toxicity (grade 4 hematologic and/or grade 3 or more non-hematologic) was observed in the three patients who received 0.06 mg/kg/day (Level 1). Of the seven patients who received 0.09 mg/kg/day (Level 2), one patient developed grade 4 hypoxemia and grade 4 thrombocytopenia, and another developed grade 4 neutropenia. Of the seven patients treated at Level 2, one with cutaneous T-cell lymphoma attained complete remission, and one with mantle cell lymphoma, one with chronic lymphocytic leukemia and one with adult T-cell leukemia-lymphoma attained partial remission. A pharmacokinetic analysis of the seven patients without leukemic cells showed that their area under the concentration versus time curves of plasma cladribine increased dose-dependently from 2661.3 +/- 300.4 nM x h at Level 1 (n = 3) to 3411.3 +/- 341.0 nM x h at Level 2 (n = 4) (P = 0.034). We conclude that the recommended phase II dose of cladribine (0.09 mg/kg/day as a seven-day continuous i.v. infusion) in Caucasian patients can be safely administered to Japanese patients. The encouraging results prompted us to plan subsequent phase II studies of cladribine against adult T-cell leukemia-lymphoma, hairy cell leukemia and indolent lymphoma. | lld:pubmed |
| pubmed-article:9255268 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9255268 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9255268 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9255268 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9255268 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9255268 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9255268 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:9255268 | pubmed:issn | 0368-2811 | lld:pubmed |
| pubmed-article:9255268 | pubmed:author | pubmed-author:KobayashiYY | lld:pubmed |
| pubmed-article:9255268 | pubmed:author | pubmed-author:OguraMM | lld:pubmed |
| pubmed-article:9255268 | pubmed:author | pubmed-author:SuzukiRR | lld:pubmed |
| pubmed-article:9255268 | pubmed:author | pubmed-author:OhashiYY | lld:pubmed |
| pubmed-article:9255268 | pubmed:author | pubmed-author:KinoshitaTT | lld:pubmed |
| pubmed-article:9255268 | pubmed:author | pubmed-author:HottaTT | lld:pubmed |
| pubmed-article:9255268 | pubmed:author | pubmed-author:KozuruMM | lld:pubmed |
| pubmed-article:9255268 | pubmed:author | pubmed-author:TobinaiKK | lld:pubmed |
| pubmed-article:9255268 | pubmed:author | pubmed-author:NarabayashiMM | lld:pubmed |
| pubmed-article:9255268 | pubmed:author | pubmed-author:UikeNN | lld:pubmed |
| pubmed-article:9255268 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9255268 | pubmed:volume | 27 | lld:pubmed |
| pubmed-article:9255268 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9255268 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9255268 | pubmed:pagination | 146-53 | lld:pubmed |
| pubmed-article:9255268 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:9255268 | pubmed:meshHeading | pubmed-meshheading:9255268-... | lld:pubmed |
| pubmed-article:9255268 | pubmed:meshHeading | pubmed-meshheading:9255268-... | lld:pubmed |
| pubmed-article:9255268 | pubmed:meshHeading | pubmed-meshheading:9255268-... | lld:pubmed |
| pubmed-article:9255268 | pubmed:meshHeading | pubmed-meshheading:9255268-... | lld:pubmed |
| pubmed-article:9255268 | pubmed:meshHeading | pubmed-meshheading:9255268-... | lld:pubmed |
| pubmed-article:9255268 | pubmed:meshHeading | pubmed-meshheading:9255268-... | lld:pubmed |
| pubmed-article:9255268 | pubmed:meshHeading | pubmed-meshheading:9255268-... | lld:pubmed |
| pubmed-article:9255268 | pubmed:meshHeading | pubmed-meshheading:9255268-... | lld:pubmed |
| pubmed-article:9255268 | pubmed:meshHeading | pubmed-meshheading:9255268-... | lld:pubmed |
| pubmed-article:9255268 | pubmed:meshHeading | pubmed-meshheading:9255268-... | lld:pubmed |
| pubmed-article:9255268 | pubmed:meshHeading | pubmed-meshheading:9255268-... | lld:pubmed |
| pubmed-article:9255268 | pubmed:meshHeading | pubmed-meshheading:9255268-... | lld:pubmed |
| pubmed-article:9255268 | pubmed:meshHeading | pubmed-meshheading:9255268-... | lld:pubmed |
| pubmed-article:9255268 | pubmed:meshHeading | pubmed-meshheading:9255268-... | lld:pubmed |
| pubmed-article:9255268 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9255268 | pubmed:articleTitle | Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group. | lld:pubmed |
| pubmed-article:9255268 | pubmed:affiliation | Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. | lld:pubmed |
| pubmed-article:9255268 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9255268 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9255268 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:9255268 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:9255268 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
